YAFO Life Science is the investment banking division of YAFO Capital with a focus on global biopharma and medtech licensing, financing, and M&A, representing leading healthcare clients from China, U.S., Europe, Israel, and Japan. YAFO Life Science is dedicated to bringing global healthcare (pharmaceutical and medical device) products to China, aiming at bridging the gap between global medical technologies and the Chinese market. We also represent leading Chinese biotech companies to explore licensing/partnership opportunities globally
Our core business is to help our clients understand the local regulatory and market environment, identify the best local strategic partners and advise them in licensing and financing deals to enter the Chinese or overseas market successfully.
YAFO team consists of 25 on the ground professionals with diverse Wall Street and healthcare industry background performing formulating strategy, execution, due diligence and communication work on behalf of our clients in China. Our professional team offers cross-cultural expertise while navigating entry into China markets and access to additional resources and funds.
Over the last decade, we have built strong relationships with the top 100+ pharma and medtech companies in China, successfully helped many of our global clients to raise capital and license-out their products in the Chinese market.
• Host conferences and roadshows for foreign companies to meet Chinese investors
• Representing clients in China, attending conferences and trade shows to meet partners/investors
In 2010, recognizing that the healthcare reform and industry growth was spurring a new wave of emerging Chinese healthcare companies, a group of investors led the efforts to organize China Healthcare Investment Conference (CHIC). This prestigious event has since grown into the most powerful platform to promote and nurture the Chinese healthcare investment ecosystem and further develop the industry.